Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 11
2004 14
2005 28
2006 18
2007 23
2008 23
2009 19
2010 17
2011 22
2012 24
2013 27
2014 23
2015 18
2016 23
2017 24
2018 24
2019 20
2020 15
2021 22
2022 17
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

379 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM. Armand P, et al. Among authors: engert a. J Clin Oncol. 2018 May 10;36(14):1428-1439. doi: 10.1200/JCO.2017.76.0793. Epub 2018 Mar 27. J Clin Oncol. 2018. PMID: 29584546 Free PMC article. Clinical Trial.
Hodgkin lymphoma.
Küppers R, Engert A, Hansmann ML. Küppers R, et al. Among authors: engert a. J Clin Invest. 2012 Oct;122(10):3439-47. doi: 10.1172/JCI61245. Epub 2012 Oct 1. J Clin Invest. 2012. PMID: 23023715 Free PMC article. Review.
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.
Bröckelmann PJ, Bühnen I, Meissner J, Trautmann-Grill K, Herhaus P, Halbsguth TV, Schaub V, Kerkhoff A, Mathas S, Bormann M, Dickhut A, Kaul H, Fuchs M, Kobe C, Baues C, Borchmann P, Engert A, von Tresckow B. Bröckelmann PJ, et al. Among authors: engert a. J Clin Oncol. 2023 Feb 20;41(6):1193-1199. doi: 10.1200/JCO.22.02355. Epub 2022 Dec 12. J Clin Oncol. 2023. PMID: 36508302 Clinical Trial.
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, Sasse S, Topp MS, Schäfer E, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Wilhelm M, Maschmeyer G, Thiemer J, Dührsen U, Meissner J, Viardot A, Eich H, Baues C, Diehl V, Rosenwald A, von Tresckow B, Dietlein M, Borchmann P, Engert A. Fuchs M, et al. Among authors: engert a. J Clin Oncol. 2019 Nov 1;37(31):2835-2845. doi: 10.1200/JCO.19.00964. Epub 2019 Sep 10. J Clin Oncol. 2019. PMID: 31498753 Clinical Trial.
The Fifth Year of HemaSphere.
Cools J, Engert A. Cools J, et al. Among authors: engert a. Hemasphere. 2021 Jun 1;5(6):e588. doi: 10.1097/HS9.0000000000000588. eCollection 2021 Jun. Hemasphere. 2021. PMID: 34095771 Free PMC article. No abstract available.
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
Bröckelmann PJ, Goergen H, Keller U, Meissner J, Ordemann R, Halbsguth TV, Sasse S, Sökler M, Kerkhoff A, Mathas S, Hüttmann A, Bormann M, Zimmermann A, Mettler J, Fuchs M, von Tresckow B, Baues C, Rosenwald A, Klapper W, Kobe C, Borchmann P, Engert A. Bröckelmann PJ, et al. Among authors: engert a. JAMA Oncol. 2020 Jun 1;6(6):872-880. doi: 10.1001/jamaoncol.2020.0750. JAMA Oncol. 2020. PMID: 32352505 Free PMC article. Clinical Trial.
Hodgkin lymphoma: Introduction.
Engert A, Vassilakopoulos TP. Engert A, et al. Semin Hematol. 2016 Jul;53(3):137-8. doi: 10.1053/j.seminhematol.2016.05.001. Epub 2016 May 12. Semin Hematol. 2016. PMID: 27496303 No abstract available.
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R. Younes A, et al. Among authors: engert a. J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26. J Clin Oncol. 2012. PMID: 22454421 Free PMC article. Clinical Trial.
Introducing the HemaSphere Controversies Series.
Eichenauer DA, Cools J, Engert A. Eichenauer DA, et al. Among authors: engert a. Hemasphere. 2019 Sep 27;3(5):e296. doi: 10.1097/HS9.0000000000000296. eCollection 2019 Oct. Hemasphere. 2019. PMID: 31942547 Free PMC article. No abstract available.
379 results